B-Cell Lymphoma

The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly diagnosed diffuse large B-cell lymphoma, according to study results published in Journal of Clinical Oncology.

Patients with relapsed or refractory large B-cell lymphoma who received lisocabtagene maraleucel had similar response rates regardless of the type of center providing the chimeric antigen receptor T-cell therapy, according to study results.

Combining natural killer cells with high-dose chemotherapy and autologous stem cell transplant did not increase toxicity among patients with B-cell non-Hodgkin lymphoma, according to results presented at TCT Meetings Digital Experience.

CAR T-cell therapy can serve as a frontline treatment option for patients with high risk B-cell lymphomas with CD-19 CAR T-cells, according to a presentation from ASH Annual Meeting and Exposition.

First-line therapy with axicabtagene ciloleucel induced an objective response in 85% of patients with high-risk large B-cell lymphoma, according to phase 2 study results presented at the virtual ASH Annual Meeting and Exposition.

Frederick Locke, MD, co-leader of the Immunology Program at Moffitt Cancer Center, discussed follow-up data from the JULIET trial presented at the ASH Annual Meeting and Exposition

The FDA for a second time delayed a decision on a biologics license application for lisocabtagene maraleucel, a chimeric antigen receptor T-cell therapy for the treatment of adults with relapsed or refractory large B-cell lymphoma.

Switching a B-cell lymphoma or leukemia treatment from CD20-directed immunotherapy to an alternative option may offer a successful alternative to desensitization protocols in instances of severe drug hypersensitivity.

Atezolizumab, obinutuzumab and venetoclax combined produced a durable response in relapsed/refractory diffuse large B-cell lymphoma but presented best in low tumor burden cases, according to a poster presented at ASCO20 Virtual Scientific Sessions.

In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.